Given that RRAD induces EGFR and STAT3 activation and RRAD knockdown sensitizes chemoresistant cancer cells to cytotoxic drugs8,9, targeting STAT3 with oxelaidin or butamirate may attenuate temozolomide resistance and glioblastoma recurrence after treatment. Here, EGFR is linked to glioblastoma.